Mesoblast

Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure (DREAM HF-1)

Mesoblast’s mesenchymal adult lineage stem cells secrete diverse biomolecules, supporting their use in regenerative medicine therapies.

Mesenchymal Precursor Cells Reduce Mortality and Major Morbidity in Ischaemic Heart Failure with Inflammation: DREAM-HF – European Journal of Heart Failure, November 2024

Allogeneic Mesenchymal Precursor Cells (MPC) in Diabetic Nephropathy: A Randomized, Placebo-controlled, Dose Escalation Study – E BioMedicine, October 2016

Intravenous Human Mesenchymal Precursor Stem Cells Improve Functional Recovery and Neuronal Activity in a Rat Stroke Model – Neuroscience, 2013

Mesoblast’s proprietary technologies are underscored by scientific excellence, with data reported in a wide range of peer-reviewed publications:

Mesoblast develops allogeneic mesenchymal lineage cell therapies to treat severe inflammatory conditions by modulating immune responses and reducing inflammation.

Mesoblast and its Board of Directors are committed to implementing and achieving an effective corporate governance framework to ensure that the Company is managed effectively and in an honest and ethical way.

W. R. Grace Building 1114 6th Avenue, 4th Floor New York, NY 10036

The company’s lead mesenchymal stromal cell therapy is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients aged 2 months and older.

Effective date: September 8, 2026 Last updated: September 8, 2026

Mesoblast gains FDA approval for a new potency assay, the **T-cell Proliferation Inhibition BioAssay (TIBA)**, enabling commercial release of its **Ryoncil® (remestemcel-L)** product lots. The assay supports stability monitoring for all new batches of the **FDA-approved mesenchymal stromal cell (MSC) therapy** targeting inflammatory diseases. The company now proceeds with full-scale manufacturing under the updated regulatory framework.

Sep 2026BioSpaceNews article

Mesoblast Limited holds a webcast to present its latest financial results and corporate updates. The company provides regenerative medicine therapies and focuses on stem cell technology. Investors and stakeholders review performance metrics and strategic developments during the session.

Aug 2026GlobeNewswireNews article

Mesoblast Limited reports strong financial performance for its Ryoncil® product, driving expansion in its allogeneic cellular medicine pipeline for inflammatory diseases. The company highlights operational progress and a robust growth trajectory in the first half of fiscal year 2026. Financial results reflect profitability supporting further development in its therapeutic portfolio.

Feb 2026nasdaq.comNews article

Ryoncil® achieves a 60% sales growth in the December quarter, reaching **US$35.1 million** in revenue. The company, backed by Mesoblast Limited, reports strong performance in its latest financial update. This marks a significant rise from previous quarterly figures, driven by increased demand for its regenerative medicine products.

Jan 2026GlobeNewswireNews article